GSK’s SR One among investors in CRISPR Therapeutics’ $89m fundraise

SR One, the independent corporate venture capital arm of GlaxoSmithKline, was one of the lead investors in two rounds of financing totaling $89m for gene-editing biopharmaceutical company CRISPR Therapeutics.